Objective: Terminally ill patients with hematological malignancy tend to be treated aggressively. We aimed to clarify the status and costs of antimicrobial treatment of patients dying with hematological malignancies.
Methods: This retrospective study was conducted in a Japanese acute hospital between September 2010 and August 2015.